VCU Researchers Develop VCU-1012 to Reduce Psychedelic Side Effects
Researchers have re-engineered the psychedelic compound quipazine into a new molecule, VCU-1012, that maintains therapeutic serotonin 2A receptor binding in mice while eliminating the serotonin 3 receptor activation responsible for nausea. The development arrives as a Phase 3 trial for an LSD-derived depression therapy also reports positive topline results. The race to separate the therapeutic … Read more